JEANINE FEBRES: Open Payments
NPI 1912208760 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,336 in 91 payments from 16 companies in 2025. Trend: 2023 $887 · 2024 $2,052 · 2025 $2,336
Food & beverage: $2,336
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $459 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $267 |
| Madrigal Pharmaceuticals | 9 | $239 |
| Janssen Biotech, Inc. | 12 | $212 |
| Novo Nordisk Inc | 6 | $203 |
| Regeneron Healthcare Solutions, Inc. | 4 | $195 |
| Lilly USA, LLC | 9 | $152 |
| Phathom Pharmaceuticals, Inc. | 3 | $149 |
| QOL Medical, LLC | 4 | $149 |
| Celltrion USA Inc. | 5 | $87 |
Products named: REZDIFFRA, ENTYVIO, TREMFYA, Wegovy, RINVOQ, OMVOH, VOQUEZNA, Sucraid.
Industry payments across FL — which companies pay providers there.
